Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Karyopharm Therapeutics (KPTI) over the last 11 years, with Q4 2025 value amounting to $5.0 million.

  • Karyopharm Therapeutics' Change in Acquisitions & Divestments fell 6923.08% to $5.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $43.4 million, marking a year-over-year decrease of 7191.22%. This contributed to the annual value of $43.4 million for FY2025, which is 7191.22% down from last year.
  • Karyopharm Therapeutics' Change in Acquisitions & Divestments amounted to $5.0 million in Q4 2025, which was down 6923.08% from $4.8 million recorded in Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Change in Acquisitions & Divestments peaked at $69.0 million during Q1 2021, and registered a low of $4.8 million during Q3 2025.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $31.1 million (2021), whereas its average is $34.0 million.
  • As far as peak fluctuations go, Karyopharm Therapeutics' Change in Acquisitions & Divestments soared by 11337.6% in 2023, and later plummeted by 8300.86% in 2025.
  • Karyopharm Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $30.5 million in 2021, then increased by 4.34% to $31.8 million in 2022, then surged by 36.49% to $43.4 million in 2023, then crashed by 62.56% to $16.2 million in 2024, then tumbled by 69.23% to $5.0 million in 2025.
  • Its last three reported values are $5.0 million in Q4 2025, $4.8 million for Q3 2025, and $18.3 million during Q2 2025.